Comparison of the efficacy of sitagliptin with pioglitazone on dexamethasone-induced hepatic steatosis, dyslipidemia, and hyperglycemia in albino rats

Paul Mathai1*, Nagendra Nayak1, Mamtha Rao2, G. M. Nitasha Bhat1, K. Vinodraj1, N. Chandralekha1, D. Rajesh1, T. K. Chethan3

INTRODUCTION

Two-third of the world’s population lives in the Asia Pacific region where prevalence of diabetes has reached epidemic proportion. With China and India being the most populous nations on the globe, it is believed that over 150 million diabetes patients reside in the region with more than 95% being of type 2 diabetes mellitus (T2DM).1 The precise mechanism by which obesity leads to insulin resistance and to T2DM is not completely known but it may be related to several biochemical factors such as abnormalities in free fatty acids, adipokines, leptin, and other substances.2 Dysregulation of the secretion and/or activity of endogenous glucocorticoids are increasingly implicated in a number of common disorders that pose a growing clinical burden, such as obesity, Type 2 diabetes, the metabolic syndrome, hypertension and depression.3

Glucocorticoid action on target tissues is determined by the density of “nuclear” receptors and intracellular...
metabolism by the two isozymes of 11β-hydroxysteroid dehydrogenase (11β-HSD) which catalyze interconversion of active cortisol and corticosterone with inert cortisone and 11-dehydrocorticosterone. 11β-HSD type 1, a predominant reductase in most intact cells, catalyzes the regeneration of active glucocorticoids, thus amplifying cellular action. 11β-HSD1 is widely expressed in liver, adipose tissue, muscle, pancreatic islets, adult brain, inflammatory cells, and gonads. 11β-HSD1 is selectively elevated in adipose tissue in obesity where it contributes to metabolic complications. Long-term upregulation of 11β-HSD1 in metabolically active tissues may follow prenatal “stress” hormone exposure and indicates a novel mechanism for fetal origins of adult obesity and the metabolic syndrome. An increased frequency of hypertension, central obesity, impaired glucose tolerance, diabetes, and hyperlipoproteinemia has been described in patients with subclinical Cushing’s syndrome.

Since the advent of glucocorticoid therapy for autoimmune disease in the 1940s, their widespread application has led to the concurrent therapy-limiting discovery of many adverse metabolic side effects. Unanticipated hyperglycemia associated with the initiation of glucocorticoids often leads to preventable hospital admissions, prolonged hospital stays, increased risks for infection, and reduced graft function in solid organ transplant recipients. Challenges in managing steroid-induced diabetes stem from wide fluctuations in post-prandial hyperglycemia and the lack of clearly defined treatment protocols.

Numerous studies have documented a strong relationship between hepatic steatosis and insulin resistance. In addition, there are several reports about the association of hepatic steatosis and glucocorticoids. Studies in mice have demonstrated that metformin reverses aminotransferase abnormalities, steatosis, and inflammation in mouse models of non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Many clinical trials have evaluated the useful effects of metformin on patients with NAFLD and NASH. A meta-analysis including five randomized controlled trials (RCT) concluded that metformin did not improve steatosis, lobular inflammation, hepatocellular ballooning, and fibrosis in patients with NASH. A recent guideline indicates that metformin has no significant effect on liver histology and therefore, it is not recommended as a specific treatment for liver disease in adults with NASH.

A large meta-analysis that included 11 RCTs (862 participants, 38% diabetic) showed that Thiazolidinediones (TZDs) improve steatosis, hepatocellular ballooning and necroinflammation, delay fibrosis progression and ameliorate hepatic, muscle and adipose tissue insulin resistance with more consistent cardiovascular benefits with pioglitazone. Pioglitazone is associated with adverse events such as bladder cancer, bone loss, weight gain, painful swollen legs, and congestive heart failure. It would be a good choice to use TZDs for the treatment of NAFLD only in patients with T2DM who are also candidates for treatment with a TZD. In a study conducted in mice, exendin-4, a glucagon-like peptide-1 (GLP-1) agonist, reduced hepatic steatosis by improving insulin sensitivity. A recent meta-analysis including 4442 patients indicated that liraglutide decreased aminotransferase levels and that this effect was dose-dependent. It is concluded that controlled studies are needed to show the efficacy of GLP-1 analogs in NAFLD and NASH treatment. In rat models, dipeptidyl peptidase type 4 (DPP4) inhibitors improve hepatic steatosis by increasing insulin sensitivity and decreasing hepatic triglyceride levels. To date, there is no published controlled trial with these agents in humans.

METHODS

Experimental animal

Healthy adult rats of Wistar strain weighing around 240-270 g were used in the present study. The animals were housed in clean polypropylene cages and maintained in a well-ventilated temperature-controlled animal house with constant 12 hrs light/dark schedule. The animals were fed with standard rat pellet diet, and clean drinking water was made available ad libitum. All animal procedures have been approved, and prior permission from the Institutional Animal Ethical Committee (IAEC) was obtained as per prescribed guidelines (KSHEMA/IAEC/43/2011).

Experimental methods

A total of 24 rats were divided into four groups with six rats in each group. Body weight was checked for all groups on day 1, day 7, and day 12.

- First group received dexamethasone alone in a dose of 8 mg/kg intraperitoneally for 6 days to induce metabolic changes and considered as dexamethasone control.
- Second group received sitagliptin 100 mg/kg orally, 6 days before dexamethasone and 6 days during dexamethasone administration.
- Third group received pioglitazone 45 mg/kg orally, 6 days before dexamethasone and 6 days during dexamethasone administration.
- Fourth group did not receive any medication and was considered as normal control.

Rats were fasted overnight; blood was collected by retro-orbital sinus puncture for fasting blood sugar, lipid profile, and 2 hrs after a glucose load of 2 g/10 ml/kg IP (postprandial blood sugar). Rats were sacrificed by cervical dislocation. Liver was dissected out; liver weight, liver volume were measured. Livers were stored in 10% formalin and sent for histopathological analysis. The details of the study method are given in Table 1.
Statistical analysis

Data management was done in excel after cleaning and coding. Then, the data were transferred to SPSS package version 17.0 for analysis. The values presented as mean±standard deviation. Independent t-test was used to compare between two groups. ANOVA with Scheffe’s post-hoc test was done for multiple comparisons. A value of p=0.05 was considered statistically significant.

RESULTS

Effect of sitagliptin on blood sugar levels in rats

The blood sugar levels of four groups are presented in Table 2. An increase in blood sugar levels was seen in the dexamethasone group as compared to the normal group. A significant decrease in the fasting and postprandial blood glucose levels was observed in the sitagliptin- and pioglitazone-treated groups as compared to dexamethasone control group (p<0.01). The fasting blood glucose levels in the sitagliptin-treated group were comparable to pioglitazone group (p=0.342). A corresponding significant decrease in postprandial blood glucose levels was observed (p<0.01) in the pioglitazone group as compared with sitagliptin group (Table 2).

Effect of sitagliptin on lipids

The lipid profiles of four groups are presented in Table 2. An increase in total cholesterol, triglycerides, and decrease in high-density lipoprotein (HDL) was seen in the dexamethasone group as compared to the normal group. A significant decrease in the total cholesterol and triglyceride, and increase in HDL levels were observed in the sitagliptin- and pioglitazone-treated groups as compared to dexamethasone control group (p<0.01). The total cholesterol, triglyceride, and HDL levels in the sitagliptin-treated group were comparable to pioglitazone group (p=0.158, p=0.149, p=0.289) (Table 2).

Effect of sitagliptin on liver weight and liver volume

The liver weight and liver volume of four groups are presented in Table 3. An increase in the liver weight and liver volume was seen in the dexamethasone group as compared to the normal group. A significant decrease in the liver...
weight and liver volume was observed in the sitagliptin- and pioglitazone-treated groups as compared to dexamethasone control group (p<0.01). The liver weight and liver volume in the sitagliptin-treated group were comparable to pioglitazone group (p=0.378, p=0.095) (Table 3).

**Effect of sitagliptin on body weight**

The body weights of four groups are presented in Table 3. There was a weight loss seen in the dexamethasone group as compared to the normal group on day 12. A significant increase in the body weight was observed in the sitagliptin- and pioglitazone-treated groups as compared to dexamethasone control group (p<0.01). The body weight in the sitagliptin-treated group was comparable to pioglitazone group (p=0.280) (Table 3).

**Histopathological observations**

The Normal control group rats showed normal hepatocytes. The dexamethasone treated group showed increase in the size of hepatocytes, cytoplasm is vesicular to clear. Fat deposition was observed. The hepatocytes in rats treated with pioglitazone and sitagliptin were smaller in size and had reduced fat deposition compared to dexamethasone treated group (Figure 1).

**DISCUSSION**

Metformin and pioglitazone are the two insulin sensitizers used in current clinical practice.26 Considering their adverse effect profiles, metformin is more acceptable than pioglitazone. Even then, there is a situation in practice for the use of pioglitazone either as add-on or as a substitute to metformin.25 This is due to the difference in the mechanisms of action of metformin and pioglitazone. There is a need for an alternative insulin sensitizer whose efficacy is comparable to pioglitazone. Hence, it was decided to use pioglitazone as the standard.

Glucocorticoids are implicated in insulin resistance and T2DM. Large doses of glucocorticoids are used for therapeutic purposes, produce insulin resistance and diabetes mellitus for which insulin sensitizers like pioglitazone have been used commonly.27 However, pioglitazone has several adverse effects, which limits its use. GLP-1 RA is useful in preventing features of insulin resistance.28 Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP4 inhibition in diabetic mice.24 Sitagliptin is preferred to liraglutide, as it is effective orally.

Present study is done to compare the effects of sitagliptin with that of pioglitazone, on dexamethasone-induced hyperglycemia, dyslipidemia, and hepatic steatosis. Sitagliptin was as effective as pioglitazone in reducing the dyslipidemia, hepatic steatosis, and fasting hyperglycemia. However, it was not as effective in reducing blood glucose levels, 2 hrs after a glucose load. This may be because glucose load was given by intraperitoneal route. This is the limitation of this study. It is concluded that once-daily administration of sitagliptin might be useful in preventing the dyslipidemia, hepatic steatosis, and fasting hyperglycemia due to glucocorticoids excess.

**ACKNOWLEDGMENTS**

The authors acknowledge sincere thanks to the Department of Pharmacology (K.S Hegde Medical Academy), Nitte University Central Research Laboratory and the staff of animal house for the facilities granted for the research work.

Funding: Funded by Nitte University
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Animal Ethical Committee of (K.S.Hegde Medical Academy), Nitte University, Mangalore, Karnataka, India

**REFERENCES**

1. Bagley A, Malabu UH. Diabetes epidemic in the Asia Pacific region: has hemoglobin A1C finally earned its place as a diagnostic tool? Asian Pac J Trop Biomed. 2014;4(2):85-9.
2. Ginter E, Simko V. Type 2 diabetes mellitus, pandemic in the 21st century. Adv Exp Med Biol. 2012;771:42-50.

3. Buckingham JC. Glucocorticoids: Exemplars of multitasking. Br J Pharmacol. 2006;147 Suppl 1:S258-68.

4. Chapman K, Holmes M, Seckl J. 11ß-hydroxysteroid dehydrogenases: Intracellular gate-keepers of tissue glucocorticoid action. Physiol Rev. 2013;93(3):1139-206.

5. Nyirenda MJ, Carter R, Tang JI, de Vries A, Schlumbohm C, Hillier SG, et al. Prenatal programming of metabolic syndrome in the common marmoset is associated with increased expression of 11beta-hydroxysteroid dehydrogenase type 1. Diabetes. 2009;58(12):2873-9.

6. Terzolo M, Reimondo G, Bovio S, Angeli A. Subclinical Cushing’s syndrome. Pituitary. 2004;7(4):217-23.

7. Hwang JL, Weiss RE. Steroid-induced diabetes: A clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev. 2014;30(2):96-102.

8. Giby VG, Ajith TA. Role of adipokines and peroxisome proliferator-activated receptors in nonalcoholic fatty liver disease. World J Hepatol. 2010;2(8):570-9.

9. Dekker MJ, Su Q, Baker C, Rutledge AC, Adeli K. Fructose: Enhanced Nrf2 activity worsens insulin resistance, hepatic steatosis, and the metabolic syndrome. Am J Physiol Endocrinol Metab. 2010;299(5):E685-94.

10. Xu J, Kulkarni SR, Donepudi AC, More VR, Slitt AL. Enhanced Nrfl2 activity worsens insulin resistance, impairs lipid accumulation in adipose tissue, and increases hepatic steatosis in leptin-deficient mice. Diabetes. 2012;61(12):3208-18.

11. Ahmed A, Rabbitt E, Brady T, Brown C, Guest P, Bujalska IJ, et al. A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease. PLoS One. 2012;7(2):e29531.

12. Patel R, Patel M, Tsai R, Lin V, Bookout AL, Zhang Y, et al. LXRß is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. J Clin Invest. 2011;121(1):431-41.

13. Macfarlane DP, Forbes S, Walker BR. Glucocorticoids and fatty acid metabolism in humans: Fueling fat redistribution in the metabolic syndrome. J Endocrinol. 2008;197(2):189-204.

14. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000;6(9):998-1003.

15. Kita Y, Takamura T, Misu H, Ota T, Kurita S, Takeshita Y, et al. Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis. PLoS One. 2012;7(9):e43056.

16. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;358(9285):893-4.

17. Bugianesi E, Gentilcore E, Manni R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol. 2005;100(5):1082-90.

18. Haukeland JW, Konopski Z, Egggesho HB, von Vollkann HL, Raschpichler G, Bjørø K, et al. Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial. Scand J Gastroenterol. 2009;44(7):853-60.

19. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55(4):885-904.

20. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-23.

21. Ding X, Saxena NK, Lin S, Gupta NA, Anania FA. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology. 2006;43(1):173-81.

22. Armstrong MJ, Houslihan DD, Rowe IA, Clausen WH, Elbrand B, Gough SC, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther. 2013;37(2):234-42.

23. Akaslan SB, Degertekin CK, Yilmaz G, Cakir N, Arslan M, Toruner FB. Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats. Metab Syndr Relat Disord. 2013;11(4):243-50.

24. Shirakawa J, Fujii H, Ohnuma K, Sato K, Ito Y, Kaji M, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes. 2011;60(4):1246-57.

25. Arab JP, Candia R, Zapata R, Muñoz C, Arancibia JP, Poniachik J, et al. Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review. World J Gastroenterol. 2014;20(34):12182-201.

26. Hanefeld M, Pfitzner A, Forst T, Kleine I, Fuchs W. Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: The PIOCOMB study. Cardiovasc Diabetol. 2011;10:65.

27. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care. 2002;25(3):517-23.

28. Ahlkvist L, Brown K, Ahrén B. Upregulated insulin secretion and molecular approach to understanding and treatment. Br J Pharmacol. 2006;147 Suppl 1:S258-68.

29. Hovind H, Eriksen J, Christensen BB, Andersen AM, Jørgensen HK, Ravn P. Randomized controlled trial of metformin versus pioglitazone in the treatment of type 2 diabetes. Lancet. 1999;354(9188):1607-11.

30. Mathai P, Nayak N, Rao M, Bhat GM, Vinodraj K, Chandrakheila N, Rajesh D, Chethan TK. Comparison of the efficacy of sitagliptin with pioglitazone on dexamethasone-induced hepatic steatosis, dyslipidemia and hyperglycemia in albino rats. Int J Basic Clin Pharmacol. 2015;4:60-4.